NU7441 (KU-57788)

Catalog No.S2638

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.

Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

NU7441 (KU-57788) Chemical Structure

NU7441 (KU-57788) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

NU7441 (KU-57788) is available in the following compound libraries:

DNA-PK Inhibitors with Unique Features

  • Non-specific DNA-PK Inhibitor

    PI-103 DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.

  • Most Potent DNA-PK Inhibitor

    PIK-75 DNA-PK, IC50=2 nM.

  • Newest DNA-PK Inhibitor

    KU-0060648 Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Classic DNA-PK Inhibitor

    NU7026 Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Product Information

  • Compare DNA-PK Inhibitors
    Compare DNA-PK Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays.
Targets DNA-PK [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3K [1]
(Cell-free assay)
ATM [1]
(Cell-free assay)
ATR [1]
(Cell-free assay)
IC50 14 nM 1.7 μM 5 μM >100 μM >100 μM
In vitro NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. [2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. [3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. [4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. [5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H1770MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjuOJdUUUN3ME2wMlAzOTR|IN88US=>NVXtboV4W0GQR1XS
A172NV7GVXZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTDTolKSzVyPUCuNVU{OTZizszNM{PuXHNCVkeHUh?=
NCI-H526M3S3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PRcmlEPTB;MD6yPFQxPyEQvF2=M2LJe3NCVkeHUh?=
HDLM-2NXTtdFRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjXV3p3UUN3ME2wMlMzOzR3IN88US=>MoPMV2FPT0WU
HuO-3N1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjxOIdKUUN3ME2wMlQ3PjN4IN88US=>NEHoOWFUSU6JRWK=
NCI-SNU-1MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmr0TWM2OD1yLk[wPVk1KM7:TR?=M3\r[3NCVkeHUh?=
SK-N-ASM{faeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TDRWlEPTB;MD62NlIyPiEQvF2=NGjucnZUSU6JRWK=
LoVoMkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3QdItKSzVyPUCuPFY4PDlizszNMUPTRW5ITVJ?
LAMA-84M1TRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTBwOUi4N|Mh|ryPNFTFXJBUSU6JRWK=
CTB-1NYfteGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vObmlEPTB;MT6xNVU1PiEQvF2=NU\uNZVFW0GQR1XS
KP-N-YSMnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXf4fVJqUUN3ME2xMlE1OjNzIN88US=>NUDzT4lqW0GQR1XS
HHMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[5UIFKSzVyPUGuNVgxQTNizszNMWDTRW5ITVJ?
CHL-1M4GzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTlfHVwUUN3ME2xMlIyOzZ6IN88US=>NUTGd4VuW0GQR1XS
NB7NXK3NI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7nUlF5UUN3ME2xMlI1PzR3IN88US=>NX[1O2ZPW0GQR1XS
HL-60NVS4[5RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTFwM{ixPUDPxE1?NH\ydmFUSU6JRWK=
639-VMmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwNESxNlgh|ryPM4X6fnNCVkeHUh?=
NCI-H1793MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHIOHFKSzVyPUGuOFU5PCEQvF2=MkPFV2FPT0WU
NEC8NUTmbIdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHH5c4NKSzVyPUGuOVU{PSEQvF2=MWLTRW5ITVJ?
PA-1NWLa[oJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjkR4xKSzVyPUGuOVgzQTRizszNNV;ZTmdMW0GQR1XS
D-423MGNUDFb5dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTFwNkmzOlEh|ryPNGXlfJpUSU6JRWK=
NCI-H292M4fOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHGT|RuUUN3ME2xMlc1ODF|IN88US=>M3nicnNCVkeHUh?=
SK-MEL-1NVHrPGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjmOGVKSzVyPUGuO|k1PzlizszNMlzNV2FPT0WU
LB2241-RCCMl64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXTT5dxUUN3ME2yMlE1OTR4IN88US=>M3jve3NCVkeHUh?=
SK-MEL-3M4TwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTJwMU[0PUDPxE1?MXLTRW5ITVJ?
MHH-PREB-1NYW2S|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T4OmlEPTB;Mj6xOlYxQSEQvF2=MYjTRW5ITVJ?
BFTC-905M{TVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3DNoxKSzVyPUKuNVY3QDdizszNMonEV2FPT0WU
Ramos-2G6-4C10MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEL2bHBKSzVyPUKuNVk6ODlizszNMWLTRW5ITVJ?
G-361NV3CflAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnaPGhCUUN3ME2yMlIyPjhizszNM2fzS3NCVkeHUh?=
MOLT-4M2rUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{f6TmlEPTB;Mj6yNVg5QCEQvF2=MV3TRW5ITVJ?
DELMlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTJwM{W1OlQh|ryPNUnHSGJDW0GQR1XS
MV-4-11NYnWcmV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHOTWM2OD1{LkO3N|kh|ryPMkn4V2FPT0WU
SK-NEP-1M3zhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjhO4hUUUN3ME2yMlM5Pzh|IN88US=>MYXTRW5ITVJ?
RS4-11MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDiTWM2OD1{LkW2NFI{KM7:TR?=NHftS4tUSU6JRWK=
HuH-7MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPKTWM2OD1{LkW2O|AzKM7:TR?=NX;BPIxSW0GQR1XS
A101DNH[wUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTJwNkGzN|gh|ryPMUfTRW5ITVJ?
KG-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTJwNke5NlQh|ryPNVHn[Zd[W0GQR1XS
KALS-1M1LFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTJwNkm2N|Mh|ryPMVfTRW5ITVJ?
VMRC-RCZMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXn5dmM6UUN3ME2yMlc4OzJ6IN88US=>MmDsV2FPT0WU
SK-UT-1Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDZTWM2OD1|LkG1N|Eh|ryPMYXTRW5ITVJ?
SW962NEftepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\Qe2hKSzVyPUOuNlA{PTJizszNMkX6V2FPT0WU
DBTRG-05MGMoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTQc4lKSzVyPUOuNlgxQDVizszNNYTkOZdVW0GQR1XS
PANC-08-13MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jXWWlEPTB;Mz60NVI4QCEQvF2=MoO3V2FPT0WU
QIMR-WILNX7pN2tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUi4Vo53UUN3ME2zMlQyOzRzIN88US=>MnizV2FPT0WU
SK-MEL-30MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TaUmlEPTB;Mz60NlU6QCEQvF2=MmrjV2FPT0WU
697NH\aNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13BOmlEPTB;Mz60OFk6OyEQvF2=NFzo[25USU6JRWK=
NYMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIG5PJFKSzVyPUOuOFUxOjJizszNNEfobXpUSU6JRWK=
ES7MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\SUWlEPTB;Mz60OlczQSEQvF2=M1;uSnNCVkeHUh?=
JVM-3NVvOS5NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmG3TWM2OD1|LkS4NFc4KM7:TR?=Mo\nV2FPT0WU
U031MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTNwNUmzOlgh|ryPNYG0d3JCW0GQR1XS
BHT-101NVHMWIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Pn[WlEPTB;Mz61PVk5PSEQvF2=NH\ofZdUSU6JRWK=
8305CNWLzfYo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvSSZJKSzVyPUOuOlE4OzZizszNNIKzOGNUSU6JRWK=
MG-63MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzuTWM2OD1|Lk[yOlc3KM7:TR?=NVKzSYZXW0GQR1XS
NOS-1M17qPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfLTWM2OD1|Lk[1N|EzKM7:TR?=MYTTRW5ITVJ?
YH-13NWjscoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTNwOEexPFkh|ryPNH2wbFdUSU6JRWK=
LXF-289NWfvR5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTNwOUGwOFEh|ryPM{TrOXNCVkeHUh?=
GOTOMlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHy0SlhKSzVyPUOuPVE1QSEQvF2=MoDsV2FPT0WU
EKVXMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTRwMkK1NlQh|ryPMmqzV2FPT0WU
CAL-51NVnUdHRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHHTWM2OD12LkK0PFU1KM7:TR?=MYPTRW5ITVJ?
AN3-CANWm2O|BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTRwMkW4NVMh|ryPMojIV2FPT0WU
IA-LMM2C5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1H0O2lEPTB;ND6yO|k{PSEQvF2=NICyUW5USU6JRWK=
KU-19-19MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17VZWlEPTB;ND6zNlkzOSEQvF2=NHHpeW9USU6JRWK=
A704M{DJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTRwNEC4PFgh|ryPMnnDV2FPT0WU
RH-18NVHVXI82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3tZXYyUUN3ME20MlQ1QTV|IN88US=>M3XsRXNCVkeHUh?=
IST-MEL1NFnVOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvlZZRuUUN3ME20MlU5OjZ|IN88US=>Moi4V2FPT0WU
LU-134-AM2ewbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXpNHJpUUN3ME20MlU6Pjh3IN88US=>MmTrV2FPT0WU
SF126MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nacWlEPTB;ND62NFcyPSEQvF2=M1HLPXNCVkeHUh?=
EFO-27MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTRwNk[1NlUh|ryPMWfTRW5ITVJ?
SN12CMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTRwN{G4PVgh|ryPNYHJPIZJW0GQR1XS
L-363MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHtSYpCUUN3ME20Mlc4OTF4IN88US=>NX:1fohWW0GQR1XS
MEL-HOMor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTRwN{e5PFkh|ryPNH2yfZRUSU6JRWK=
TYK-nuMlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rENmlEPTB;ND64NFEzQCEQvF2=MnXrV2FPT0WU
MDA-MB-415Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDHZ2JKSzVyPUWuNFA{OTRizszNM2TPUHNCVkeHUh?=
HCC70M1;Jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrFTWM2OD13LkCzPVM6KM7:TR?=MY\TRW5ITVJ?
IGROV-1NFTVbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rGO2lEPTB;NT6yOVI6OiEQvF2=NYLEWmplW0GQR1XS
NCI-H1355M17GV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXoTWM2OD13LkK5OkDPxE1?NVvxOVBsW0GQR1XS
23132-87NE\rNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTVwM{KwNlQh|ryPM{HEWHNCVkeHUh?=
NB69M4r4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTVwM{K0NkDPxE1?NIfUR5ZUSU6JRWK=
HSC-2NEfKRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFflV5pKSzVyPUWuOFE4PzNizszNMkHZV2FPT0WU
KYSE-410MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTjbmt3UUN3ME21MlQ4PjN4IN88US=>NYTGUW1CW0GQR1XS
GCIYNWD6OWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTVwNUGzO|gh|ryPM3PtfnNCVkeHUh?=
A427Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\WTWM2OD13LkWzOlYyKM7:TR?=NFzOdo9USU6JRWK=
ChaGo-K-1M2nCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XIXGlEPTB;NT61OlU6QSEQvF2=NVnyPXFSW0GQR1XS
PFSK-1NWLYRlM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG[4RoVKSzVyPUWuOlIyQTRizszNMnrrV2FPT0WU
MLMAMoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\ZPGlEPTB;NT64N|YxPiEQvF2=MWfTRW5ITVJ?
RVH-421NHHB[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nlTmlEPTB;Nj6wO|M{QCEQvF2=M1rlUHNCVkeHUh?=
LB1047-RCCMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTZwMUe1NlIh|ryPMkjxV2FPT0WU
MHH-NB-11MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13oe2lEPTB;Nj6zNlczOSEQvF2=MYTTRW5ITVJ?
J-RT3-T3-5NXjwcYF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml:2TWM2OD14Lk[zNlkyKM7:TR?=Ml3CV2FPT0WU
UM-UC-3MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnpN|lwUUN3ME22MlY1OzN2IN88US=>NWjLTosxW0GQR1XS
IST-SL1M{L6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGD2RlNKSzVyPU[uOlk{PjlizszNNUjxNZhkW0GQR1XS
NB14MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\sWmlEPTB;Nj63PVc3OSEQvF2=NYjL[IxjW0GQR1XS
NBsusSRMmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTZwOEK1NFIh|ryPNYG5fHpIW0GQR1XS
D-263MGNXzjO2ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjGSWhKSzVyPU[uPVExPjhizszNMWrTRW5ITVJ?
NCI-H2347MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3mTWM2OD14LkmzNlE{KM7:TR?=NEXZc4VUSU6JRWK=
ES8NVXCdHlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUL5bmlzUUN3ME22Mlk4PTh6IN88US=>NWL1eIh5W0GQR1XS
786-0NUDWcIV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmD6TWM2OD15LkC5O|g3KM7:TR?=NWXJTmY4W0GQR1XS
EPLC-272HNEHaR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnT3TWM2OD15LkG2NlQ3KM7:TR?=M3frbnNCVkeHUh?=
CAPAN-1MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jDR2lEPTB;Nz6yOFM2QSEQvF2=MVvTRW5ITVJ?
NCI-H82NFSzSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDUTWM2OD15LkK2OlU6KM7:TR?=NYDOO4N[W0GQR1XS
G-402MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTdwM{CwOVEh|ryPM3X4N3NCVkeHUh?=
SW982NFqxNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XNbWlEPTB;Nz6zNFIxOyEQvF2=MYjTRW5ITVJ?
OVCAR-4NYDoOXNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1qxUWlEPTB;Nz6zNVMzQCEQvF2=Mo\oV2FPT0WU
KARPAS-299M3PzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjnTWM2OD15LkOyOlIzKM7:TR?=MXnTRW5ITVJ?
MIA-PaCa-2NIfYNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnK3TWM2OD15LkO2PFI{KM7:TR?=M1TJOHNCVkeHUh?=
AU565MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\2XIVKSzVyPUeuOVk5OzNizszNNIjrXnpUSU6JRWK=
GAMGNXr3VHBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjwWFZ4UUN3ME23MlY1OTNzIN88US=>MXvTRW5ITVJ?
HuO9NGrmcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTdwN{G3OFMh|ryPNXTPfIR5W0GQR1XS
ACNMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3RSVJ5UUN3ME23Mlc1OzNizszNNGjoUXJUSU6JRWK=
RO82-W-1NVuwOIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYqwcYRyUUN3ME23Mlc1PTN|IN88US=>MmrTV2FPT0WU
NKM-1M2D6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jSfmlEPTB;Nz63OFk2PSEQvF2=NUn0Tng1W0GQR1XS
CAL-12TM2HWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{WyO2lEPTB;Nz65OFM2OiEQvF2=NGnkOWlUSU6JRWK=
FADUNYrmVJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWK1U4hyUUN3ME24MlA{PjV2IN88US=>NUn2XY1lW0GQR1XS
NCI-H28NUXv[5JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\EVVFxUUN3ME24MlE3QTZ{IN88US=>MmT4V2FPT0WU
LCLC-97TM1M3LsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHaTWM2OD16LkKxNVIzKM7:TR?=NWjHcHhPW0GQR1XS
CHP-134NFjkXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoW4TWM2OD16LkK0NVg2KM7:TR?=M{DNOXNCVkeHUh?=
HT-1080NWT5bY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvIVGhKSzVyPUiuNlUxQTNizszNNFHFVodUSU6JRWK=
PC-3Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILzSIpKSzVyPUiuNlc{QTJizszNM1[yRnNCVkeHUh?=
SNU-449MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFznW2lKSzVyPUiuNlc6OyEQvF2=Ml7tV2FPT0WU
VA-ES-BJM3PoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRThwM{S2PFYh|ryPMUHTRW5ITVJ?
HTMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4P3bWlEPTB;OD6zOlQ6KM7:TR?=NFLaXItUSU6JRWK=
HOSMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRThwM{e1PFkh|ryPM{Xub3NCVkeHUh?=
KNS-62MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1WwVmlEPTB;OD6zO|c3OiEQvF2=MVvTRW5ITVJ?
OAW-42NGn3VFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoC5TWM2OD16Lkm1PVY1KM7:TR?=NGHJe5lUSU6JRWK=
A549MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vhWWlEPTB;OT6wPVYyOiEQvF2=NUPlWVBKW0GQR1XS
CAKI-1M3rLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\tUmlEPTB;OT6xOlYyKM7:TR?=MnraV2FPT0WU
HCC1937M3fpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorrTWM2OD17Lk[5PFY2KM7:TR?=NGHGNpNUSU6JRWK=
GI-ME-NM{\j[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLsTWM2OD17LkewNVM4KM7:TR?=MkHwV2FPT0WU
DU-4475MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fGWmlEPTB;OT65Olk{QSEQvF2=NX;JWWhVW0GQR1XS
EM-2Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4e3bGlEPTB;MUCuNlQzPiEQvF2=Mn32V2FPT0WU
NCI-H1755MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLBTWM2OD1zMD6yOFI5KM7:TR?=M1;nUnNCVkeHUh?=
NCI-H1437MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELO[3ZKSzVyPUGwMlU4OjVizszNNH7Z[4xUSU6JRWK=
VM-CUB-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnhbYhKSzVyPUGwMlYyPjRizszNM4ruSnNCVkeHUh?=
A2058Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLVZWVvUUN3ME2xNE43PDB2IN88US=>M3nzc3NCVkeHUh?=
BPH-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rOUWlEPTB;MUCuO|E1PSEQvF2=Mo\iV2FPT0WU
NB5NGDrRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXmflVKSzVyPUGwMlc2PTlizszNMYPTRW5ITVJ?
G-401MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFu0UYxKSzVyPUGwMlc3OjZizszNMm\yV2FPT0WU
CAL-72MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTFyLkiwPVQh|ryPMYfTRW5ITVJ?
SK-MEL-28NWq0cWFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnhbYJKSzVyPUGwMlgzODJizszNMUnTRW5ITVJ?
C32NIfE[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTFyLkizOFch|ryPNXnVNlRIW0GQR1XS
NCI-H1155M3;hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vBeWlEPTB;MUCuPFM4PiEQvF2=MoqzV2FPT0WU
BB49-HNCMnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z1OGlEPTB;MUCuPFU5PiEQvF2=NVLIfVhHW0GQR1XS
GMS-10NIGyemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XROWlEPTB;MUCuPFk4OSEQvF2=MmPSV2FPT0WU
K5MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NET5[2lKSzVyPUGwMlkxPzFizszNMlL6V2FPT0WU
OS-RC-2NUfsO49nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XKR2lEPTB;MUGuNFU2QSEQvF2=M1PhUXNCVkeHUh?=
HTC-C3NESxRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzjTWM2OD1zMT6wO|E1KM7:TR?=NF75U|NUSU6JRWK=
LB996-RCCNXjtW20zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHW2c4pKSzVyPUGxMlA4OjNizszNMlPWV2FPT0WU
NCI-H1563MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXjd3FKSzVyPUGxMlExOTFizszNMYLTRW5ITVJ?
CAL-54MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUG3V|RjUUN3ME2xNU41QDFzIN88US=>MkSwV2FPT0WU
WM-115MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1:3fGlEPTB;MUGuOlgzPCEQvF2=MYnTRW5ITVJ?
COLO-684NVraOJRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmH6TWM2OD1zMT63NlY4KM7:TR?=MUjTRW5ITVJ?
HOP-62Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTlVJBnUUN3ME2xNU44PTB6IN88US=>MV3TRW5ITVJ?
NCI-H650NVW1bGk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml2yTWM2OD1zMT64PVYyKM7:TR?=M1rBVXNCVkeHUh?=
TE-11MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIn2eGJKSzVyPUGxMlk{OTVizszNNXjQbopsW0GQR1XS
COLO-679M4L2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvxTWM2OD1zMT65OFYh|ryPNELB[lJUSU6JRWK=
FTC-133NVXFZVdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfkTWM2OD1zMj6wNFc3KM7:TR?=NEjEO4VUSU6JRWK=
D-283MEDMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17GeGlEPTB;MUKuNFU3QSEQvF2=M{nxTnNCVkeHUh?=
SK-PN-DWNYPY[YRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjUTZR7UUN3ME2xNk4yQTB{IN88US=>M4DufXNCVkeHUh?=
BALL-1M{LZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\VUY5KSzVyPUGyMlI3PjJizszNMW\TRW5ITVJ?
GT3TKBM1ThbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvuW3RKSzVyPUGyMlMxPzRizszNMUDTRW5ITVJ?
HOP-92NH;IbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF{LkWyN|Mh|ryPMV\TRW5ITVJ?
M14MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELBN4FKSzVyPUGzMlA{OzVizszNMVTTRW5ITVJ?
SKG-IIIaM2PHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTF|LkC1OVQh|ryPMVHTRW5ITVJ?
BeckerMoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHmyOYJKSzVyPUGzMlA2QCEQvF2=NXTsXIFwW0GQR1XS
ES5Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTF|LkGzOVYh|ryPNHq1XlJUSU6JRWK=
NCI-H2030NUfXW5RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjXPZE4UUN3ME2xN{4zODZ{IN88US=>Mlq1V2FPT0WU
SNU-423MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTF|LkO4NUDPxE1?MoXuV2FPT0WU
CP50-MEL-BNHP4RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTF|Lk[yN|Ih|ryPNXrJdFBIW0GQR1XS
NCI-H1092NVnQZ4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLFPI9OUUN3ME2xN{44PDd3IN88US=>NIS3NVZUSU6JRWK=
8-MG-BAMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnlVHBKSzVyPUGzMlc2OTNizszNNXfK[5oxW0GQR1XS
CAL-27MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TI[2lEPTB;MUSuNFczPyEQvF2=MYnTRW5ITVJ?
AGSMl;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWf0ZWl{UUN3ME2xOE4yOzF7IN88US=>MnTyV2FPT0WU
MZ2-MELMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\IR4dKSzVyPUG0MlE1QDhizszNNH\uVFBUSU6JRWK=
BFTC-909MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrXRlFKSzVyPUG0MlUxPTVizszNNVfYc3VFW0GQR1XS
D-566MGM{Xqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTF2Lke3NFYh|ryPNUixZ5Y2W0GQR1XS
MZ7-melMnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPkepNlUUN3ME2xOU4yODZ5IN88US=>NFm2R2FUSU6JRWK=
TE-5MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTyZY5KSzVyPUG1MlI{OzNizszNNGG0WmNUSU6JRWK=
647-VNGe5RnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Pud2lEPTB;MUWuNlcxPSEQvF2=NVvzblRIW0GQR1XS
DMS-114NULNUYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrUNYhFUUN3ME2xOU4{OjlzIN88US=>MnX1V2FPT0WU
ME-180NUHWU2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjOTWM2OD1zNT60O|g{KM7:TR?=MmnLV2FPT0WU
MS-1M{Hvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnPV3FPUUN3ME2xOU42PjJ|IN88US=>MnvjV2FPT0WU
NUGC-3M4jqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWm4TWpVUUN3ME2xOU43OjR3IN88US=>NG[4WphUSU6JRWK=
GB-1M{PtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTF3Lk[0N|ch|ryPNF24fYtUSU6JRWK=
LOXIMVIMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmm1TWM2OD1zNT64PVE6KM7:TR?=NWryZXdpW0GQR1XS
NCI-H1304MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTF3Lki5Nlgh|ryPM3z6cHNCVkeHUh?=
KURAMOCHIM1PxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HlTGlEPTB;MUWuPVcyKM7:TR?=MYrTRW5ITVJ?
SW1783MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWq4UXdjUUN3ME2xOk4xQTl|IN88US=>NHrzU|lUSU6JRWK=
EGI-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYC3fWhbUUN3ME2xOk42OzZ3IN88US=>NIr2fIlUSU6JRWK=
KGNM4HFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXUbJdGUUN3ME2xOk42PTh4IN88US=>NHvTdmZUSU6JRWK=
PANC-03-27NEHNUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrBRY9KSzVyPUG2Mlc3PjJizszNMnfiV2FPT0WU
RH-1NXHkZZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXq[5FYUUN3ME2xOk45OjVizszNM{LxSXNCVkeHUh?=
HT-1376NV3CZW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDOTWM2OD1zNj64OFQ3KM7:TR?=MmHvV2FPT0WU
ZR-75-30MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLLSGtWUUN3ME2xOk46OzZzIN88US=>NWrNUJBUW0GQR1XS
TI-73MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jMVmlEPTB;MU[uPVQxQCEQvF2=MlHWV2FPT0WU
TK10NIHEXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vue2lEPTB;MUeuNFA4QSEQvF2=M4nCeHNCVkeHUh?=
SW684NHmwNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYntRotjUUN3ME2xO{4xOTV2IN88US=>MXfTRW5ITVJ?
RPMI-8866M{DjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4L5Z2lEPTB;MUeuNFY6QSEQvF2=Mme4V2FPT0WU
LNCaP-Clone-FGCMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTF5LkWyNFEh|ryPMmnyV2FPT0WU
NCI-H2291MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTF6LkSzOFUh|ryPNXHlfGUzW0GQR1XS
T47DM1[1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jZU2lEPTB;MUiuOFg5KM7:TR?=M2mxbXNCVkeHUh?=
A204MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ixdmlEPTB;MUiuOVQ2OiEQvF2=NYTsco9tW0GQR1XS
HT-144M{XWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvwdJdKSzVyPUG4Mlc1OjdizszNMlvMV2FPT0WU
MDA-MB-361MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnflTWM2OD1zOT6wO|E1KM7:TR?=Ml:1V2FPT0WU
HCC1806NET2VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnGWolKSzVyPUG5MlE2QTFizszNNYTJPG5PW0GQR1XS
NCI-H596MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvnTWM2OD1zOT62N|kyKM7:TR?=MVrTRW5ITVJ?
K-562Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTF7Lki5NlYh|ryPNHXMXphUSU6JRWK=
D-336MGNUCxO5piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjNVmxlUUN3ME2xPU46OzJ{IN88US=>MW\TRW5ITVJ?
SK-MEL-2MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PYemlEPTB;MkCuNVU2QSEQvF2=MYnTRW5ITVJ?
HEC-1MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrhSGt4UUN3ME2yNE41QTd6IN88US=>M2q1eHNCVkeHUh?=
EW-13MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3OTHBvUUN3ME2yNE42PDR|IN88US=>NH7ZToxUSU6JRWK=
Hs-578-TM1fsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTJyLkW1PFMh|ryPMl;QV2FPT0WU
SJSA-1NWDKSpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PxWmlEPTB;MkCuOVY5QCEQvF2=MU\TRW5ITVJ?
RCC10RGBMn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrZ[FJKSzVyPUKwMlY4OTlizszNM3m2NHNCVkeHUh?=
LAN-6Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTJzLkCzPVYh|ryPMV\TRW5ITVJ?
NCI-H1048NEXOUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zYdWlEPTB;MkGuNlI2QCEQvF2=Ml7jV2FPT0WU
CW-2M4XDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH61WY1KSzVyPUKxMlI4ODVizszNMmXxV2FPT0WU
HCC2157NGn0VWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDvTWM2OD1{MT6zOkDPxE1?NXW3UWluW0GQR1XS
EW-22NYriV5NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PjemlEPTB;MkGuN|c3KM7:TR?=NXXXSFVlW0GQR1XS
A253MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnOTWM2OD1{MT60OFgyKM7:TR?=NWHXNHVDW0GQR1XS
BE-13NHTWcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrndYZKSzVyPUKxMlYyOTNizszNMkTxV2FPT0WU
KINGS-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYqyWVRLUUN3ME2yNU43OzF4IN88US=>M36zS3NCVkeHUh?=
ETK-1M2DIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTJzLkixOVIh|ryPM4W5PHNCVkeHUh?=
NCI-H2452NUK0fXQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTJzLki2OFch|ryPMk\oV2FPT0WU
HPAF-IIM13y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrrS2pKSzVyPUKxMlg6OjNizszNMmKzV2FPT0WU
D-542MGM2L2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTJzLkmwOlkh|ryPMojiV2FPT0WU
NCI-H630NGHVbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Tad2lEPTB;MkKuNFI6PiEQvF2=M2j2bHNCVkeHUh?=
TGBC11TKBMl\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHiSXhEUUN3ME2yNk4xPDlizszNMULTRW5ITVJ?
BCPAPM3nXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUSwR2lOUUN3ME2yNk43OTFizszNMWTTRW5ITVJ?
HLEMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlf6TWM2OD1{Mj62PVch|ryPNV;X[WhJW0GQR1XS
NCI-H727NHvTbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfyOFY{UUN3ME2yNk44OzVizszNNITtO3ZUSU6JRWK=
RDNWe0[5VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXmTWM2OD1{Mj63OVE5KM7:TR?=NXK4dYJiW0GQR1XS
NCI-H522NEjm[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLlV2tKSzVyPUKyMlg1OzFizszNMYHTRW5ITVJ?
CGTH-W-1M{fGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jHXWlEPTB;MkOuNFY1OSEQvF2=NGPwUIRUSU6JRWK=
SK-LU-1NUXyUW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLicIdWUUN3ME2yN{41Pjh|IN88US=>MoDRV2FPT0WU
BB65-RCCMmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moq4TWM2OD1{Mz63PFY{KM7:TR?=NG\obXJUSU6JRWK=
HSC-3Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJ|Lki1Nlch|ryPNYftNHdIW0GQR1XS
SK-MES-1M3TXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\zfYNKUUN3ME2yOE4xOTZzIN88US=>NIPvO5dUSU6JRWK=
DBNEjB[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TMPWlEPTB;MkSuNVAzQCEQvF2=NYnR[4Q{W0GQR1XS
HO-1-N-1NFLrPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{D0cWlEPTB;MkSuN|A6OyEQvF2=M1jv[nNCVkeHUh?=
MKN1NHvHTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTJ2Lk[4JO69VQ>?MnzBV2FPT0WU
MN-60M2iwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJ2Lki1NVkh|ryPM1\ZbXNCVkeHUh?=
8505CMmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJ3LkG4OFUh|ryPNXnTRZpOW0GQR1XS
COLO-320-HSRMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTJ3LkKyNFgh|ryPMonGV2FPT0WU
BB30-HNCMmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULCNnljUUN3ME2yOU4zPDh|IN88US=>NFvqXnVUSU6JRWK=
KM12MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3BW2JwUUN3ME2yOU42QDB5IN88US=>MnH0V2FPT0WU
NB13M1Lhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ3LkW4PVgh|ryPNETJT|NUSU6JRWK=
HCC2998NWXZPXkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\HTWM2OD1{Nj6wNlg{KM7:TR?=NGXrPIJUSU6JRWK=
U-118-MGMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfL[JlPUUN3ME2yOk4xQDB6IN88US=>NY\USmI1W0GQR1XS
NB10MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJ4LkKzOEDPxE1?NUjqfodrW0GQR1XS
SK-LMS-1NYDNU|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjlTWM2OD1{Nz6wO|A1KM7:TR?=NHPj[25USU6JRWK=
SW1573NIWxS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfLTWM2OD1{Nz6xNUDPxE1?NWLhU4dXW0GQR1XS
LB373-MEL-DNFv4eVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG[5R5FKSzVyPUK3MlEzQTRizszNM3i3bXNCVkeHUh?=
DK-MGNFnObWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlqxTWM2OD1{Nz6xPFE4KM7:TR?=NEjoNGRUSU6JRWK=
RMG-IMmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nQemlEPTB;MkeuNlAzQSEQvF2=MXPTRW5ITVJ?
SW1088NFPTb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HNe2lEPTB;MkeuOVA1OiEQvF2=NFjkTZBUSU6JRWK=
SK-OV-3M1vNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjtW3RKSzVyPUK3Mlc2QTNizszNNWjoN2VxW0GQR1XS
KP-N-YNMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmGxTWM2OD1{Nz64NFQ{KM7:TR?=M13KXHNCVkeHUh?=
RPMI-7951MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDrTWM2OD1{OD6yOFU3KM7:TR?=NXfhUYdlW0GQR1XS
CaR-1MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTJ6LkW1PFIh|ryPM13udHNCVkeHUh?=
MKN7Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jHOGlEPTB;MkiuOVk3PCEQvF2=MnTIV2FPT0WU
CHP-212MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXS2eVhXUUN3ME2yPE44PDBzIN88US=>M2TJNXNCVkeHUh?=
KYSE-450NHv2RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFu0fZBKSzVyPUK4MlgxQTFizszNNGn0T|lUSU6JRWK=
RXF393NX7ncWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnCcJZ7UUN3ME2yPU4zQTB4IN88US=>M4WwRnNCVkeHUh?=
P30-OHKNXHGOm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{D6VmlEPTB;MkmuN|A1QCEQvF2=M33FR3NCVkeHUh?=
Ca9-22MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX25PHk3UUN3ME2yPU41Ojl7IN88US=>NGrjW4NUSU6JRWK=
RT-112NWrpTJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTJ7LkS2NVEh|ryPNE\zRWVUSU6JRWK=
ES1M2\DZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrP[lNKSzVyPUK5Mlg2PDRizszNM1;W[XNCVkeHUh?=
HCE-4MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLBWI5KSzVyPUK5Mlg4QDZizszNM3LLdHNCVkeHUh?=
AM-38NE\IWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDnR3NKSzVyPUOwMlA3ODZizszNNXmzUGxjW0GQR1XS
AsPC-1NFfLbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTNyLkiwOVMh|ryPMnLwV2FPT0WU
TE-9NWjkS3VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrEb2VKSzVyPUOwMlg4OzdizszNM3HXe3NCVkeHUh?=
HuP-T4NXXQWGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;vWpIyUUN3ME2zNE46PjN6IN88US=>M2P3PHNCVkeHUh?=
LB2518-MELNYnDNZR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTNzLkC3OFQh|ryPMnuyV2FPT0WU
NCI-H1703MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1uxXWlEPTB;M{GuNFkxPSEQvF2=NH\J[YlUSU6JRWK=
NCI-H2228M{PwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PFOGlEPTB;M{GuOFY2OSEQvF2=MnPiV2FPT0WU
SCC-4M4TMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PSUWlEPTB;M{GuPVE5OSEQvF2=NGTYcpVUSU6JRWK=
KNS-81-FDNXjsc3N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3RbFRKSzVyPUOyMlAyOjhizszNMl3BV2FPT0WU
NTERA-S-cl-D1NEOxVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTN{LkC3N|kh|ryPM3vveHNCVkeHUh?=
DaoyM4rne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTN{LkC4N|gh|ryPM1vDWHNCVkeHUh?=
ES4NYLnV2t1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLUUWJIUUN3ME2zNk4{QTJ{IN88US=>NIXpc3dUSU6JRWK=
MHH-ES-1NIrDeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILaSpVKSzVyPUOyMlQ5PzJizszNMorYV2FPT0WU
C-33-ANF;FXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXYcVV1UUN3ME2zNk44PzJ6IN88US=>MkTaV2FPT0WU
BHYMmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DSRWlEPTB;M{KuPVQ6PSEQvF2=M{W5OXNCVkeHUh?=
Detroit562M1TWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFG2bHZKSzVyPUOzMlY3PTdizszNNXj4RY1zW0GQR1XS
EW-1NF7pRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;aTWM2OD1|Mz65N|IzKM7:TR?=MX;TRW5ITVJ?
NCI-H1395MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zkcmlEPTB;M{SuNFc6QSEQvF2=MnXMV2FPT0WU
KM-H2NHKwbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFK3OJBKSzVyPUO2MlQ4PDNizszNMUnTRW5ITVJ?
NCI-H520M3fJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTN4Lke1OFEh|ryPM2Cwe3NCVkeHUh?=
D-392MGMmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTN5LkOzOFQh|ryPNXvJOZRZW0GQR1XS
NOMO-1MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTN5LkiwPFkh|ryPMkXWV2FPT0WU
TE-6MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnf6TWM2OD1|OD6xNlQh|ryPNX;lVIUzW0GQR1XS
HT-3MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\VTWM2OD1|OD60OFM3KM7:TR?=M2HkTnNCVkeHUh?=
RPMI-8226M1rMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPhTWM2OD1|OD65OVE6KM7:TR?=MkTkV2FPT0WU
U251MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLsTWM2OD1|OT6wNVI1KM7:TR?=NU\4U4JLW0GQR1XS
GCTMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVu3bWVtUUN3ME2zPU4yQDV{IN88US=>MVnTRW5ITVJ?
A431NF7vbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2O0UWlEPTB;M{muNVg6PCEQvF2=MXrTRW5ITVJ?
TE-12NVrWN3AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEflUVNKSzVyPUO5MlI1PDhizszNMVTTRW5ITVJ?
HMV-IIM{DWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTN7LkWwOFch|ryPMnfmV2FPT0WU
IST-MES1NIi2NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWC5TIJvUUN3ME20NE4yPTB{IN88US=>MnH4V2FPT0WU
SW13MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mly4TWM2OD12MD61NVkh|ryPMWXTRW5ITVJ?
SF295M2n6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rqXWlEPTB;NECuPFA3PiEQvF2=NWeyT41mW0GQR1XS
MDA-MB-157NUDyXHVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LWRWlEPTB;NECuPVQ3OiEQvF2=NYjzT4hSW0GQR1XS
TE-1NU[0VlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYL6e2Y{UUN3ME20NU45PzF2IN88US=>NYHqTFQyW0GQR1XS
HuCCT1NXvNOVNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXQO2pKSzVyPUSyMlUzQDlizszNNVj3Wo1{W0GQR1XS
KYSE-510MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTR|LkG3OVQh|ryPNGXuU3VUSU6JRWK=
NCI-H358M{LzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17ZV2lEPTB;NESuNFMxPCEQvF2=MYjTRW5ITVJ?
SW900MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHCXZRtUUN3ME20OE4xPzV6IN88US=>NUDlSGlnW0GQR1XS
CAS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLlTWM2OD12ND6wPVkyKM7:TR?=MlyxV2FPT0WU
TE-8NF\JfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HyZWlEPTB;NESuOVY2QCEQvF2=M12ybXNCVkeHUh?=
P12-ICHIKAWANUfLdpk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LVSWlEPTB;NESuOlEyOiEQvF2=M3LRZnNCVkeHUh?=
YKG-1NV3NXG03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlf0TWM2OD12ND63PFEh|ryPM1PCV3NCVkeHUh?=
SNU-C2BMmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzJTWM2OD12ND63PVA{KM7:TR?=MWHTRW5ITVJ?
LCLC-103HNYDJUog3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7EUoJ1UUN3ME20OE45PzB|IN88US=>NFLKdYRUSU6JRWK=
U-87-MGMmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjOWXRiUUN3ME20OU4yODJ{IN88US=>M3XtZXNCVkeHUh?=
HAL-01M1LBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPETWM2OD12NT6xN|c6KM7:TR?=M2\scHNCVkeHUh?=
OVCAR-8NXr6[Yh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrnV5NKSzVyPUS1MlM2PjRizszNMkCxV2FPT0WU
KYSE-150MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrOTWM2OD12Nz6xNFUzKM7:TR?=NIe5W4lUSU6JRWK=
OE33NIPxZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTR5LkG0Nlkh|ryPM4jXb3NCVkeHUh?=
CAL-62M1rreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTR5LkSwOlgh|ryPNIS2NlRUSU6JRWK=
TCCSUPMn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vjWGlEPTB;NEeuOlI3PCEQvF2=M3HpXXNCVkeHUh?=
H4MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTR5Lk[2NlEh|ryPM{\RTnNCVkeHUh?=
CP66-MELM3Pvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTR6LkC3NFQh|ryPMnHOV2FPT0WU
SNB75M2DBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYizeZp{UUN3ME20PE4yQDd2IN88US=>NVjpbYg5W0GQR1XS
Mo-TNWjHNXVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHKTWM2OD12OD6yO|kh|ryPNGHifpRUSU6JRWK=
BT-549MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLTe4NMUUN3ME20PE4{PzJ7IN88US=>MnTQV2FPT0WU
IGR-1NWPEeVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzMZo5KSzVyPUS4MlY3PDVizszNMnvtV2FPT0WU
NCI-H1299M{\yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTVTWM2OD12OD63NlQ5KM7:TR?=M4f2VXNCVkeHUh?=
ALL-PONVnKbG1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\2NYJlUUN3ME20PU46OjZ6IN88US=>MXrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. [2]
Features

Protocol(Only for Reference)

Cell Assay: [2]

Cell lines SW620, LoVo, V3-YAC and V3 cells
Concentrations 0.5 μM or 1 μM
Incubation Time 17 hours
Method The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min 137Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 105 per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

Animal Study: [2]

Animal Models Female rude mice bearing SW620 xenografts
Formulation Sterile 0.9% sodium chloride solution
Dosages 10 mg/kg
Administration Intraperitoneally administrated

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Leahy JJ, et al. Bioorg Med Chem Lett, 2004, 14(24), 6083-6087.

[2] Zhao Y, et al. Cancer Res, 2006 , 66(10), 5354-5362.

view more

Chemical Information

Download NU7441 (KU-57788) SDF
Molecular Weight (MW) 413.49
Formula

C25H19NO3S

CAS No. 503468-95-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (7.25 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4H-1-Benzopyran-4-one, 8-(4-dibenzothienyl)-2-(4-morpholinyl)-

Frequently Asked Questions

  • Question 1
    Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?

    Answer: Slight color variation due to different processing is normal and usually doesn't interfere with the function.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA-PK Products

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • NU7026

    NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

  • KU-0060648

    KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Recently Viewed Items

Tags: buy NU7441 (KU-57788) | NU7441 (KU-57788) supplier | purchase NU7441 (KU-57788) | NU7441 (KU-57788) cost | NU7441 (KU-57788) manufacturer | order NU7441 (KU-57788) | NU7441 (KU-57788) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us